Pfizer Stock Can Go Higher

Pfizer Stock Can Go Higher by Adam Rosen last updated on March 07, 2026

Pfizer (PFE) Stock Price Can Go Higher

Pfizer is going through tough times, as evidenced by its weak financial results, and the stock price is also down. On top of that, the adjusted EPS was also very modest, and the guidance for 2026 is not that strong.

But despite all the bad news, there are several reasons why the Pfizer stock price can go higher and even reach a new all-time high.

Pfizer Has Massive Pipeline Activity Planned

A quick look at Pfizer shows it has a lot of pipeline activity planned in the next 3 years. So, if the results of these are positive, the Pfizer stock price can easily soar and reach new highs.

As oper the details operate, Pfizer is expecting good progress in around 20 clinical trials in 2026. This also includes around 10 drugs that were added to its portfolio after acquiring Metsera.

All of these 10 drugs are great, and positive results from this can easily jolt the stock price to new highs. So, there's a good chance that Pfizer's stock price could skyrocket in the next few years.

And if we talk about risks, the biggest one is that there is no guarantee that the phase 3 studies will lead to clinical wins. That's why all the drugs in the pipeline are still not factored into the stock price.

But this uncertainty is exactly what also creates a huge upside opportunity in the Pfizer stock. At the same time, it also comes with a good dose of risk, and it is not something that can simply be ignored.

Last but not least, Pfizer has successfully managed to improve its bottom line despite the decline in revenue. This is mainly due to Pfizer's ability to cut costs.

And Pfizer also pays a dividend with a high yield of almost 6.7%. So, that's also something that can attract long-term investors to the Pfizer stock.